LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651-Reference-Cited by-同舟云学术

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Published:2021-09 Issue: Volume:32 Page:S1310-S1311
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Argiris A.,Harrington K.,Tahara M.,Ferris R.L.,Gillison M.,Fayette J.,Daste A.,Koralewski P.,Mesia Nin R.,Saba N.F.,Mak M.,Álvarez Avitia M.A.,Guminski A.,Müller-Richter U.,Kiyota N.,Roberts M.,Khan T.A.,Miller-Moslin K.,Wei L.,Robert Haddad R.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study;ESMO Open;2024-08

2. Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series;Oral Oncology;2024-05

3. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma;Cancer Immunology, Immunotherapy;2024-03-02

4. Re-Irradiation of Recurrent Head and Neck Cancers Using Pulsed Reduced Dose Rate Radiotherapy: An Institutional Series;2024-01-17

5. In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck;International Journal of Radiation Oncology*Biology*Physics;2023-09